Do pharmacogenetics have a role in the dosing of vitamin K antagonists?

N Engl J Med. 2013 Dec 12;369(24):2345-6. doi: 10.1056/NEJMe1313682. Epub 2013 Nov 19.

Author

Affiliation

¹ From Harvard Medical School and the Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center - both in Boston.

PMID: 24251364
DOI: 10.1056/NEJMe1313682

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acenocoumarol / administration & dosage*
Algorithms*
Anticoagulants / administration & dosage*
Aryl Hydrocarbon Hydroxylases / genetics*
Cytochrome P-450 CYP2C9
Female
Genotype*
Humans
Male
Phenprocoumon / administration & dosage*
Vitamin K Epoxide Reductases / genetics*
Warfarin / administration & dosage*

Substances

Anticoagulants
Warfarin
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
VKORC1 protein, human
Vitamin K Epoxide Reductases
Acenocoumarol
Phenprocoumon